Published in Nat Clin Pract Gastroenterol Hepatol on January 20, 2009
Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer (2009) 3.99
Prognostic gene expression signature associated with two molecularly distinct subtypes of colorectal cancer. Gut (2011) 1.32
Irinotecan therapy and molecular targets in colorectal cancer: a systemic review. World J Gastroenterol (2009) 0.84
Thymidylate synthase gene polymorphism and survival of colorectal cancer patients receiving adjuvant 5-fluorouracil. Genet Test Mol Biomarkers (2013) 0.79
Prognostic value of colorectal cancer biomarkers. Cancers (Basel) (2011) 0.77
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med (2004) 49.02
The biology of VEGF and its receptors. Nat Med (2003) 32.13
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med (2004) 30.26
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med (2004) 18.93
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med (2000) 18.12
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol (2000) 16.83
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol (2008) 15.17
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet (2000) 12.56
Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med (2006) 12.50
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol (2003) 12.24
Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol (2004) 9.73
Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet (2007) 9.23
Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol (2007) 7.73
Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol (2007) 7.67
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol (2006) 7.05
Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol (2004) 7.04
Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med (2005) 6.22
Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol (2008) 5.78
Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet (1998) 5.65
OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study. J Clin Oncol (2006) 5.56
Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer (1998) 5.40
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol (2001) 5.25
Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol (2000) 5.20
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol (2001) 4.89
Colorectal cancer. Lancet (1999) 4.72
Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet (2007) 4.68
Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol (2003) 4.34
Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol (2007) 4.32
Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet (2007) 3.85
Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res (2000) 3.42
Preoperative radiotherapy for resectable rectal cancer: A meta-analysis. JAMA (2000) 2.76
The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer (1993) 2.23
Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol (1998) 2.11
Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers. Anticancer Drugs (1997) 1.53
Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial. Lancet (2003) 1.52
Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer. J Clin Oncol (2008) 1.46
Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer. J Clin Oncol (2007) 1.43
Functional categories of TP53 mutation in colorectal cancer: results of an International Collaborative Study. Ann Oncol (2006) 1.18
Prognostic markers of colorectal cancer: an evaluation of DNA content, epidermal growth factor receptor, and Ki-67. J Surg Oncol (1992) 1.18
Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy. J Clin Oncol (1999) 1.12
Proliferating endothelial cells and leukocyte infiltration as prognostic markers in colorectal cancer. Clin Gastroenterol Hepatol (2006) 1.05
Capecitabine: have we got the dose right? Nat Clin Pract Oncol (2008) 1.02
Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study. Ann Oncol (2006) 0.91
Prognostic value of 5-fluorouracil metabolic enzyme genes in Dukes' stage B and C colorectal cancer patients treated with oral 5-fluorouracil-based adjuvant chemotherapy. Oncol Rep (2008) 0.88
The role of molecular markers in predicting response to therapy in patients with colorectal cancer. Mol Diagn Ther (2008) 0.82
A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med (2004) 13.34
Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet (2007) 9.23
Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nat Genet (2012) 6.25
Meta-analysis of three genome-wide association studies identifies susceptibility loci for colorectal cancer at 1q41, 3q26.2, 12q13.13 and 20q13.33. Nat Genet (2010) 4.20
Common variation near CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk. Nat Genet (2012) 3.19
Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer. J Clin Oncol (2013) 2.90
Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): an open-label randomised trial. Lancet (2009) 2.59
Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. J Clin Oncol (2011) 2.55
Multiple common susceptibility variants near BMP pathway loci GREM1, BMP4, and BMP2 explain part of the missing heritability of colorectal cancer. PLoS Genet (2011) 2.47
Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial. J Clin Oncol (2010) 2.32
Open access chemical and clinical probes to support drug discovery. Nat Chem Biol (2009) 2.28
Predictive biomarkers: a paradigm shift towards personalized cancer medicine. Nat Rev Clin Oncol (2011) 2.02
The challenge of cancer control in Africa. Nat Rev Cancer (2008) 1.71
Virus-directed enzyme prodrug therapy: intratumoral administration of a replication-deficient adenovirus encoding nitroreductase to patients with resectable liver cancer. J Clin Oncol (2004) 1.54
Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. J Clin Oncol (2002) 1.52
A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma. Hepatology (2009) 1.46
Arginine methylation controls growth regulation by E2F-1. EMBO J (2012) 1.44
Defective mismatch repair in colon cancer: a prognostic or predictive biomarker? J Clin Oncol (2010) 1.34
HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy. Proc Natl Acad Sci U S A (2010) 1.26
Adjuvant chemotherapy for stage II colon cancer: less complicated than we thought. J Clin Oncol (2013) 1.26
Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. Int J Oncol (2009) 1.15
Single-dose clinical pharmacokinetic studies of gefitinib. Clin Pharmacokinet (2005) 1.14
Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: results from CALGB 9581. J Clin Oncol (2011) 1.12
Breast cancer cell-derived EMMPRIN stimulates fibroblast MMP2 release through a phospholipase A(2) and 5-lipoxygenase catalyzed pathway. Oncogene (2002) 1.08
Refinement of the associations between risk of colorectal cancer and polymorphisms on chromosomes 1q41 and 12q13.13. Hum Mol Genet (2011) 1.07
Capecitabine: have we got the dose right? Nat Clin Pract Oncol (2008) 1.02
Adjuvant chemotherapy for stage II colorectal cancer: the time is right! Nat Clin Pract Oncol (2005) 0.99
Nitroreductase: a prodrug-activating enzyme for cancer gene therapy. Clin Exp Pharmacol Physiol (2004) 0.99
A trial of adjuvant therapy in colorectal cancer: the VICTOR trial. Clin Colorectal Cancer (2003) 0.98
EnROL: a multicentre randomised trial of conventional versus laparoscopic surgery for colorectal cancer within an enhanced recovery programme. BMC Cancer (2012) 0.92
Identification of FGF receptor-binding peptides for cancer gene therapy. Cancer Gene Ther (2002) 0.89
Challenges of cancer control in developing countries: current status and future perspective. Future Oncol (2011) 0.87
CB 1954: from the Walker tumor to NQO2 and VDEPT. Curr Pharm Des (2003) 0.86
Colorectal cancer. Acta Oncol (2003) 0.85
Use of a phage display library to identify oligopeptides binding to the lumenal surface of polarized endothelium by ex vivo perfusion of human umbilical veins. J Drug Target (2003) 0.85
Tobacco: deadly in any form or disguise. Lancet (2006) 0.83
Roles of tetrahydrobiopterin in promoting tumor angiogenesis. Am J Pathol (2010) 0.82
Immune enhancement of nitroreductase-induced cytotoxicity: studies using a bicistronic adenovirus vector. Int J Cancer (2003) 0.81
Ras as a target in cancer therapy. Crit Rev Oncol Hematol (2002) 0.80
Immunotherapy for colorectal cancer. Expert Rev Anticancer Ther (2003) 0.80
Identification of oligopeptides binding to peritoneal tumors of gastric cancer. Cancer Sci (2006) 0.80
Targeted therapies: Cetuximab plus chemotherapy in patients with advanced NSCLC. Nat Rev Clin Oncol (2009) 0.80
Regional hepatic chemotherapies in the treatment of colorectal cancer metastases to the liver. Semin Oncol (2010) 0.79
Gene therapy for colorectal cancer. Br Med Bull (2002) 0.79
The nitroreductase/CB1954 enzyme-prodrug system. Methods Mol Med (2004) 0.78
The predictive and prognostic value of sex in early-stage colon cancer: a pooled analysis of 33,345 patients from the ACCENT database. Clin Colorectal Cancer (2013) 0.78
Gene profiling in early stage disease. Cancer J (2010) 0.76
Quinone oxidoreductase-2-mediated prodrug cancer therapy. Sci Transl Med (2010) 0.76
Bacteriophage biopanning in human tumour biopsies to identify cancer-specific targeting ligands. J Drug Target (2007) 0.76
Malignant peritoneal mesothelioma. Is there a new treatment? Rare Tumors (2009) 0.75
Medical oncology: A novel low-toxicity regimen for advanced colorectal cancer? Nat Rev Clin Oncol (2010) 0.75
Health diplomacy: a new approach to the Muslim world? Global Health (2014) 0.75
EUFEPS report. Contribution of academic research to discovery and development of medicines: current status and future opportunities. Eur J Pharm Sci (2005) 0.75
Clinical experience with adenovirus in cancer therapy. Curr Opin Mol Ther (2002) 0.75
Identification of an oligopeptide binding to hepatocellular carcinoma. Oncology (2007) 0.75
Curbing tobacco's toll starts with the professionals: World No Tobacco Day. Lancet (2005) 0.75
Pharmacokinetic considerations in the use of anticancer drugs during pregnancy: challenges and new developments. Expert Opin Drug Metab Toxicol (2015) 0.75
The emergence of 'omics for the management of colorectal cancer. Curr Opin Oncol (2011) 0.75